Is this Pharma stock set for a comeback? Motilal Oswal sees as much as 17% upside
Motilal Oswal, a brokerage firm, is optimistic about Gland Pharma, a pharma stock, and expects strong returns in the coming quarters. The firm maintains a ‘Buy’ rating with a target price of Rs 2,310, indicating a potential upside of 17%. Despite a dip in margins, the company's outlook remains steady, with growth expected from limited-competition products and expansion plans.